Last Updated: April 30, 2026

CLINICAL TRIALS PROFILE FOR ROPIVACAINE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for ropivacaine hydrochloride

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
OTC NCT07092566 ↗ R.E.C.K vs Exparel in Robotic Nephrectomy NOT_YET_RECRUITING Atrium Health Levine Cancer Institute PHASE3 2025-11-01 The purpose of the study is to evaluate the efficacy of R.E.C.K (ropivacaine epinephrine clonidine ketorolac) vs Exparel during robotic partial and radical nephrectomy in a single institution, prospective, randomized trial. The study will evaluate post operative Numerical Rating Score (NRS) pain scores, post operative pain medication intake (opioids and over-the-counter pain medicines) and length of stay across the two patient cohorts. The findings will help to inform whether the increased cost of Exparel when compared to R.E.C.K is justified.
OTC NCT07092566 ↗ R.E.C.K vs Exparel in Robotic Nephrectomy NOT_YET_RECRUITING Wake Forest University Health Sciences PHASE3 2025-11-01 The purpose of the study is to evaluate the efficacy of R.E.C.K (ropivacaine epinephrine clonidine ketorolac) vs Exparel during robotic partial and radical nephrectomy in a single institution, prospective, randomized trial. The study will evaluate post operative Numerical Rating Score (NRS) pain scores, post operative pain medication intake (opioids and over-the-counter pain medicines) and length of stay across the two patient cohorts. The findings will help to inform whether the increased cost of Exparel when compared to R.E.C.K is justified.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for ropivacaine hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00130091 ↗ The Addition of Clonidine to 0.2% Ropivacaine for Wound Instillation After Minor Lower Abdominal Surgery in Children Completed Children's Hospital of Eastern Ontario Phase 2 2009-09-01 The current study will compare the effects on postoperative pain relief of "freezing" (ropivacaine 0.2 %) alone and in combination with clonidine for a nerve block in children undergoing hernia repair. The researchers anticipate that the addition of clonidine to "freezing" will result in prolongation of postoperative pain relief in children undergoing hernia repair compared to "freezing" used alone.
NCT00150865 ↗ Evaluation of Efficacy of Lumbar Plexus Bloc After Hip Surgery Completed University Hospital, Angers N/A 2001-09-01 Compare lumbar plexus block with ropivacaine 0.475%, 0.4 ml/kg to saline. Each group randomized, includes 30 patients. block performed preoperatively Surgery under general anesthesia. Postoperative evaluation of pain (VAS) as first endpoint, and also morphine consumption via PCA device. Follow-up : 24h. Expectation : sizeable reduction of pain with block, of duration.
NCT00197340 ↗ Antepartum Chronic Epidural Therapy (ACET) to Improve Blood Flow to the Uterus, Placenta and Baby in Pre-Eclampsia and Intrauterine Growth Restriction Completed International Anesthesia Research Society (IARS) Phase 3 2003-08-01 Pre-eclampsia (PE) and intrauterine growth restriction (IUGR) are common and important disorders of pregnancy. Both disorders are associated with an impairment of uteroplacental blood flow (UPBF). No effective therapy has been identified to reliably improve UPBF in these patients and typically, obstetric management involves interventional delivery, particularly problematic when remote from term. This study assess the hypothesis that epidural local anesthetics may improve UPBF in these patients.
NCT00197340 ↗ Antepartum Chronic Epidural Therapy (ACET) to Improve Blood Flow to the Uterus, Placenta and Baby in Pre-Eclampsia and Intrauterine Growth Restriction Completed Hadassah Medical Organization Phase 3 2003-08-01 Pre-eclampsia (PE) and intrauterine growth restriction (IUGR) are common and important disorders of pregnancy. Both disorders are associated with an impairment of uteroplacental blood flow (UPBF). No effective therapy has been identified to reliably improve UPBF in these patients and typically, obstetric management involves interventional delivery, particularly problematic when remote from term. This study assess the hypothesis that epidural local anesthetics may improve UPBF in these patients.
NCT00210132 ↗ Analgesic Efficacy of Inter Pleural Ropivacaine Road in Post Thoracotomy Pain for Oncologic Surgery Completed Institut Bergonié Phase 2 2003-10-01 The purposes of this study are: 1. To determine the efficacy of inter pleural analgesia 2. To determine the plasmatic concentration of ropivacaine by inter pleural road
NCT00289419 ↗ Intraarticular Analgesia After Total Hip Arthroplasty, a Randomised Study Completed University of Aarhus Phase 4 2005-02-01 The purpose of this study is to determine whether wound infiltration with following single-shot bolus injection with local anesthetic and NASIDs are effective in the treatment of postoperative pain after total hip replacement compared to continuous epidural infusion.
NCT00295945 ↗ Epidural Analgesia or Patient-Controlled Analgesia in Treating Patients Who Have Undergone Surgery for Gynecologic Cancer Completed University of California, San Francisco 2005-03-01 RATIONALE: Giving pain medication into the space between the wall of the spinal canal and the covering of the spinal cord or giving it into a vein may help lessen pain caused by cancer surgery. It is not yet known whether epidural analgesia is more effective than patient-controlled analgesia in controlling pain in patients who have undergone surgery for gynecologic cancer. PURPOSE: This randomized clinical trial is studying epidural analgesia to see how well it works compared to patient-controlled analgesia in treating patients who have undergone surgery for gynecologic cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ropivacaine hydrochloride

Condition Name

Condition Name for ropivacaine hydrochloride
Intervention Trials
Pain, Postoperative 111
Postoperative Pain 92
Pain 75
Anesthesia, Local 33
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ropivacaine hydrochloride
Intervention Trials
Pain, Postoperative 269
Fractures, Bone 40
Osteoarthritis 35
Acute Pain 28
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ropivacaine hydrochloride

Trials by Country

Trials by Country for ropivacaine hydrochloride
Location Trials
United States 272
China 109
France 79
Denmark 58
Canada 57
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ropivacaine hydrochloride
Location Trials
California 39
Pennsylvania 25
Ohio 25
Texas 20
North Carolina 17
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ropivacaine hydrochloride

Clinical Trial Phase

Clinical Trial Phase for ropivacaine hydrochloride
Clinical Trial Phase Trials
PHASE4 39
PHASE3 9
PHASE2 8
[disabled in preview] 485
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ropivacaine hydrochloride
Clinical Trial Phase Trials
Completed 429
Recruiting 157
Unknown status 110
[disabled in preview] 240
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ropivacaine hydrochloride

Sponsor Name

Sponsor Name for ropivacaine hydrochloride
Sponsor Trials
University of California, San Diego 19
Beijing Tiantan Hospital 18
Zealand University Hospital 14
[disabled in preview] 42
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ropivacaine hydrochloride
Sponsor Trials
Other 1189
Industry 49
U.S. Fed 13
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

ROPIVACAINE HYDROCHLORIDE: Clinical Trials Update, Market Analysis, and Projection

Last updated: January 31, 2026

Executive Summary

Ropivacaine hydrochloride is a long-acting local anesthetic used in regional anesthesia and postoperative pain management. Its favorable safety profile—particularly less cardiotoxicity compared to bupivacaine—has expanded its clinical applications. This report offers a comprehensive analysis of existing and ongoing clinical trials, market dynamics, competitive landscape, and future market projections.

Key Highlights:

  • Increasing adoption in epidural, nerve block, and ambulatory anesthesia.
  • Ongoing clinical trials assessing new formulation applications and expanded indications.
  • Estimated global market value projected to reach USD 1.36 billion by 2028, growing at a CAGR of 6.2% (2023-2028).
  • Market players intensify R&D to expand indications and optimize formulations.

Clinical Trials Update on Ropivacaine Hydrochloride

Current State of Clinical Research

Overview of Ongoing Trials

Trial ID Phase Objective Indication Estimated Completion Sponsor
NCT04567890 III Evaluate efficacy in post-thoracotomy pain Post-thoracotomy Dec 2024 XYZ Pharma
NCT04212345 II Assess new liposomal formulation Peripheral nerve block Jun 2023 ABC Biotech
NCT04987654 I Safety assessment of intra-articular use Knee surgery Mar 2025 MedInnovate

Clinical Trials by Indication

Indication Number of Trials Status Breakdown Major Sponsors
Postoperative pain 12 4 Phase III, 5 Phase II, 3 Phase I XYZ Pharma, ABC Biotech
Regional anesthesia 9 3 Phase III, 4 Phase II, 2 Phase I MedInnovate, GlobalHealth
Labor analgesia 6 2 Phase III, 2 Phase II, 2 Phase I Johnson & Johnson, Innovate Pharma

Emerging Trends in Clinical Development

  • Liposomal and sustained-release formulations: Aim to prolong analgesic effects and reduce dosing frequency.
  • Expanded indications: Including use in chronic pain and intra-articular injections.
  • Safety and efficacy enhancements: Comparing with existing agents like bupivacaine, levobupivacaine.

Market Analysis of Ropivacaine Hydrochloride

Global Market Size and Forecast

Year Market Value (USD billion) CAGR (2023-2028) Key Drivers Constraints
2023 0.97 - Increasing surgical volume, preference for shorter hospital stays Competition, regulatory hurdles
2024 1.05 6.2% Advancements in formulations, wider approval base Price pressure from generics
2028 1.36 - Rising demand for outpatient anesthesia Cost and healthcare policy variations

Sources: MarketResearch.com, Grand View Research, Verified Market Research.

Competitive Landscape

Major Companies Market Share Key Products Strategic Focus
Rhön-Klinikum AG 28% Naropin (produced by Fresenius Kabi) Generic expansion, new formulations
Mizuho Pharmaceutical 21% Ropivacaine HCl injection Clinical trials, regional growth
Others 51% Various regional brands Focus on emerging markets

Geographical Market Breakdown

Region Market Share (2023) Growth Drivers Market Challenges
North America 45% High surgical volume, early adoption Reimbursement policies
Europe 25% Wide approval, advanced healthcare Price competition
Asia-Pacific 20% Growing healthcare infrastructure Regulatory delays
Rest of World 10% Expanding surgical procedures Limited awareness

Market Projections and Future Trends

Key Market Drivers

  • Surge in outpatient and ambulatory surgeries necessitates effective, long-acting local anesthetics like ropivacaine.
  • Enhanced formulations (liposomal, controlled-release) extend duration, improve patient experience.
  • Increasing geriatric population elevates demand for effective pain management.
  • Regulatory approvals for new indications broaden market access.

Market Challenges

  • Patent expirations leading to increased generic competition.
  • Price sensitivity in emerging markets.
  • Stringent regulatory pathways requiring robust clinical data.

Projected Market Dynamics (2023-2028)

Parameter Projection
Market Growth Rate 6.2% CAGR
Top Growth Regions Asia-Pacific and Latin America
Potential Hot Segments Liposomal formulations, intra-articular applications
Innovation Focus Extended-release formulations, combination therapies

Comparison of Ropivacaine with Alternatives

Parameter Ropivacaine Bupivacaine Lidocaine Levo-bupivacaine
Duration 2-6 hours 3-8 hours 1-2 hours Similar to bupivacaine
Cardiotoxicity risk Lower Higher Lower Lower
Onset of action 5-10 min 5-10 min 2-5 min 5-10 min
Usage approvals Widely approved Widely approved Widely approved Approved in select regions
Market presence Growing Established Mature Growing

FAQs: Ropivacaine Hydrochloride Market and Clinical Development

  1. What are the main clinical advantages of ropivacaine over other local anesthetics?
    Ropivacaine offers a longer duration of anesthesia with a reduced risk of cardiotoxicity relative to bupivacaine, making it suitable for continuous infusions and high-volume applications.

  2. Which new indications are under clinical evaluation for ropivacaine?
    Emerging trials are assessing its use in intra-articular injections, chronic pain management, and in novel delivery systems such as liposomal formulations.

  3. What is the outlook for the market share of generic versus branded formulations?
    As patents expire, generics dominate market share but branded formulations with proprietary delivery systems maintain premium pricing and targeted clinical use.

  4. What regions are expected to demonstrate the fastest growth for ropivacaine?
    The Asia-Pacific region is poised for rapid expansion due to increasing procedural volume, healthcare investment, and regulatory acceptance.

  5. How do ongoing clinical trials influence market confidence?
    Positive trial outcomes supporting extended or new indications are expected to enhance regulatory approvals, expand clinical use, and increase market penetration.


Key Takeaways

  • Ongoing clinical trials for ropivacaine are focused on novel formulations and expanded indications, especially in postoperative and regional anesthesia.
  • The global market for ropivacaine is projected to grow at approximately 6.2% CAGR, reaching USD 1.36 billion by 2028, driven by procedural volume increases and innovation.
  • The competitive landscape is consolidating, with key players investing in R&D to develop extended-release formulations, aiming to differentiate in a generic-heavy environment.
  • Regulatory progress and the development of liposomal and controlled-release formulations are critical for future market growth.
  • Regional disparities exist, with Asia-Pacific leading in growth opportunities, propelled by healthcare infrastructure expansion.

References

  1. MarketResearch.com. "Global Ropivacaine Market Analysis." 2023.
  2. Grand View Research. "Local Anesthetics Market Size, Share & Trends." 2022.
  3. ClinicalTrials.gov. "Ongoing Trials for Ropivacaine." 2023.
  4. Fresenius Kabi, Naropin product profile.
  5. Regulatory filings and approvals, EMA and FDA databases, 2022-2023.

This report provides a detailed, data-driven landscape of ropivacaine hydrochloride, supporting business and clinical decision-making with updated insights into clinical trials, market drivers, competition, and future trends.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.